92352-29-9

Usage

Uses

Used in Pharmaceutical Industry:
5-PYRIDIN-2-YL-2H-PYRAZOL-3-YLAMINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, leveraging its capacity to be modified to create molecules with targeted biological activities. This makes it instrumental in the development of new drugs with specific therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 5-PYRIDIN-2-YL-2H-PYRAZOL-3-YLAMINE serves as an intermediate in the synthesis of compounds designed to protect crops and enhance agricultural productivity, capitalizing on its structural attributes to engineer molecules with pesticidal or herbicidal properties.
Used in Medicinal Chemistry Research:
5-PYRIDIN-2-YL-2H-PYRAZOL-3-YLAMINE is utilized as a research tool in medicinal chemistry, where it aids in the exploration and understanding of molecular interactions, potentially leading to the discovery of novel therapeutic agents.
Used in Drug Discovery:
5-PYRIDIN-2-YL-2H-PYRAZOL-3-YLAMINE is employed in drug discovery processes, where its unique structure is exploited to design and synthesize new drug candidates with potential applications in treating various diseases and conditions.

InChI:InChI=1/C8H8N4/c9-8-5-7(11-12-8)6-3-1-2-4-10-6/h1-5H,(H3,9,11,12)

Upstream product

• 2524-52-9 ethyl-2-picolinate 
• 54123-21-6 3-(pyridine-2-yl)-3-oxopropanenitrile 
• 98-98-6 2-Picolinic acid 

Downstream Products

• 1610948-36-1 N¹,N³,N⁵-tris(3-(pyridin-2-yl)-1H-pyrazol-5-yl)benzene-1,3,5-tricarboxamide 
• 1433787-05-3 N¹,N³-bis(3-(pyridin-2-yl)-1H-pyrazole-5-yl)isophthalamide 
• 1258222-97-7 C₂₆H₂₈N₁₀OS 

Relevant academic research and scientific papers

FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS INHIBITORS OF PIKFYVE KINASE USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES

The present disclosure provides compounds that are inhibitors of PIKfyve and/or PI3 kinases, and are therefore useful for the treatment of neurological diseases that are treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of treatment using such compounds.

SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF

The present disclosure provides compounds that are inhibitors of PIKfyve kinases useful for the treatment of neurological diseases treatable by inhibition of PIKfyve. Also provided are pharmaceutical compositions containing such compounds, and methods of

5- OR 7-AZAINDAZOLES AS BETA-LACTAMASE INHIBITORS

The present invention relates to β-lactamase inhibitors having the following general formula (I): wherein R1-R4 and X1-X2 are defined in the specification, pharmaceutical composition thereof, and use thereof for the treatment of a bacterial infection, alone or in combination with β-lactam antibiotics and/or other antibiotics and/or other β-lactamase inhibitors.

MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein.

NOVEL ANTIPLATELET AGENT

The present invention relates to a novel antiplatelet agent and a novel compound which is an active ingredient for the agent. The present invention provides the antiplatelet agent comprising a compound represented by the formula I: wherein, X is N, or CR1d,Xb1-Xb5 are the same or different, and are nitrogen or carbon,R1a-R1d are the same or different, and are hydrogen, an optionally substituted alkyl, an optionally substituted alkoxy, an optionally substituted alkylthio, an alkenyl, a cycloalkyl, a halogen, cyano, or hydroxyl or optionally substituted by 1 or 2 alkylamino,R2 is an optionally substituted aryl or an optionally substituted heteroaryl,R3 is an optionally substituted aryl or an optionally substituted heteroaryl, or pharmaceutically acceptable salt thereof as an active ingredient.

MULTISUBSTITUTED AROMATIC COMPOUNDS AS INHIBITORS OF THROMBIN

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.

PYRAZOLO-PYRIMIDINE COMPOUNDS

The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

SYNTHESIS OF PYRAZOLES

The present invention provides methods of making HCl salts, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other

PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.